Dose-ranging Double-blind, Placebo-controlled Phase 2 Trial of GV101 for Weight Loss in Healthy Obese Participants
Latest Information Update: 09 Feb 2026
At a glance
- Drugs TDI 01 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Graviton
Most Recent Events
- 04 Feb 2026 Status changed from active, no longer recruiting to completed.
- 14 Oct 2025 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2025 Status changed from not yet recruiting to recruiting.